Compare Abbott Laboratories (ABT) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Microchip Technology Inc. — how do they compare? Abbott Laboratories trades at $108.75 (market cap $187.95B), while Microchip Technology Inc. trades at $83.46 (market cap $43.99B). The key difference: Abbott Laboratories is far larger — about 4.3× Microchip Technology Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | MCHP | |
|---|---|---|
Market Cap | $187.95B | $43.99B |
Sector | Health | Technology |
52-Week High | $136.62 | $102.97 |
52-Week Low | $82.57 | $49.02 |
Enterprise Value | $214.96B | $49.12B |
Dividend Yield | 2.32% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Microchip Technology (MCHP) trades at $81.39, down 3.9% on the day, amid a bullish technical setup and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.76 exceeding expectations. Recent news highlights robust data center revenue growth (98% last quarter) and strategic acquisitions like Hailo to bolster edge AI capabilities. Valuation metrics remain elevated with a P/E of 119.15, reflecting high growth expectations.
MCHP's outlook is positive with expanding AI infrastructure demand and raised guidance, though high valuation and recent net income pressure in 2025 pose risks. The consensus price target of $104 suggests 28% upside potential. Key risks include execution on growth initiatives and semiconductor cycle volatility. Institutional sentiment remains strongly bullish with no sell ratings among 44 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
